Centessa Pharmaceuticals Launches New Public Offering
Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical company, has officially announced its plans for an underwritten public offering of American Depositary Shares (ADSs), each representing one of their ordinary shares. The company is selling all of the offered ADSs while anticipating additional options for underwriters to purchase further shares.
Details of the Offering
The offering is conditioned upon market conditions and other factors, and there is no guarantee regarding the timeline or the magnitude of the completed deal. Centessa will grant the underwriters a 30-day option to buy up to 15% more of the offered series, enhancing their flexibility as they navigate the ratios involved.
Role of Financial Institutions
For this important offering, Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities have been appointed as the primary book-running managers. Meanwhile, Oppenheimer & Co., Truist Securities, and LifeSci Capital will serve as co-lead managers, showcasing an impressive collaboration among financial institutions.
Prospectus Information
This public offering falls under a pre-filed registration statement with the Securities and Exchange Commission (SEC). It became effective upon submission, allowing for a more efficient process. A preliminary prospectus supplement, along with the accompanying prospectus, will soon be available on the SEC's website.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals is on a mission to find transformative treatments for patients across various health challenges. They are currently pioneering a new generation of therapies through their orexin receptor 2 (OX2R) agonist program, targeting conditions like excessive daytime sleepiness, cognitive impairments, and other symptoms related to neurological disorders.
Innovative Research Goals
With a commitment to improving patient outcomes, Centessa focuses on innovative solutions in the realm of drug development. Their ongoing research addresses the needs of patients suffering from neurological, neurodegenerative, and neuropsychiatric disorders. The company is at the forefront of bringing forward therapies that could change lives.
Contact Information
For interested parties and stakeholders, Kristen K. Sheppard serves as the Senior Vice President of Investor Relations. Her expertise could be invaluable for queries related to the offering and further corporate information. She can be reached through the company's email contact for investors.
Frequently Asked Questions
1. What is the purpose of Centessa Pharmaceuticals' public offering?
The public offering aims to raise capital to support the company’s ongoing research and development efforts.
2. Who is managing the public offering?
Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are the main managers involved in the offering.
3. Where can I find more information about the offering?
Additional details, including the prospectus, will be available on the SEC website once filed.
4. What is Centessa Pharmaceuticals focused on?
Centessa is dedicated to developing innovative therapies for patients, particularly in the fields of neurological and psychiatric disorders.
5. How can I contact investor relations?
Kristen K. Sheppard can be contacted via the company email for any investor-related inquiries.
